|
Viromed Medical AG / Key word(s): Alliance Viromed Medical AG seeks extensive cooperation with a major global Group 11-Dec-2024 / 21:45 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Viromed Medical AG seeks extensive cooperation with a major global Group Pinneberg, 11 December 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; ‘Viromed’; the ‘Company’) is seeking an extensive cooperation with a major global Group that is also active in the pharmaceutical sector. Based on today’s discussions, the subject of the cooperation will be in particular the granting of a worldwide licence in favour of Viromed Medical AG for the application of cold atmospheric pressure plasma in medicine. Subject to a contractual agreement, which is expected within the next three months, Viromed expects to generate initial revenues from the use of cold atmospheric pressure plasma in the low double-digit million range as early as the second half of the 2025 financial year. Another subject of the negotiations for the establishment of an extensive cooperation is a possible participation of the global Group in Viromed or, conversely, a participation of Viromed in portfolio companies of the global Group. However, decisive negotiations on the essential terms of the respective participations are still pending. Viromed will inform the capital market about the further progress of the negotiations on the intended cooperation in accordance with its legal obligation.
Contact Viromed Medical AG Uwe Perbandt End of Inside Information 11-Dec-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Breakthrough study: inhibiting USP30 gene offers hope in treating Parkinson’s disease
Whether USP30 inhibition can serve as a disease-modifying therapy for Parkinson’s disease (PD).
November 15, 2023